我国首个“ARNI”类原研降压药获批上市；*ST吉药摘牌丨医药早参

Group 1 - The first ARNI class antihypertensive drug in China, Xinchaotuo, developed by Xinlitai, has been approved for primary hypertension treatment, enhancing the company's product line and market competitiveness [1] - The National Medical Products Administration has announced the conversion of Xiaer Ganmao Ning and Pugongying Granules from prescription to over-the-counter drugs, providing broader market opportunities for pharmaceutical companies while facing stricter regulations [2] - Jia Ying Pharmaceutical has been investigated by the China Securities Regulatory Commission for information disclosure violations, highlighting the regulatory body's zero tolerance for such infractions and promoting industry standardization [3] Group 2 - ST Jiyao's stock will be delisted on May 29 due to continuous trading below par value, emphasizing the strict "par value delisting" rules in the capital market and the need for companies to focus on market value management [4] - ST Longjin's stock will enter a delisting transition period starting June 6, reflecting the risks faced by pharmaceutical companies with poor management and sustained performance pressure, urging the industry to strengthen operational management [5]